CoChat

The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.

Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial

Open access
Moyle, Graeme, Assoumou, Lambert, de Castro, Nathalie, Post, Frank A, Curran, Adrian, Rusconi, Stefano, De Wit, Stephane, Stephan, Christoph, Raffi, François, Johnson, Margaret, Masia, Mar, Vera, Jaime, Jones, Bryn, Grove, Richard, Fletcher, Carl, Duffy, Annie, Morris, Kellie, Pozniak, Anton, Moyle, Graeme, de Castro, Nathalie, Post, Frank, Curran, Adrian, Rusconi, Stefano, De Wit, Stephane, Stephan, Christoph, Raffi, François, Johnson, Margaret, Masia, Mar, Vera, Jaime, Winston, Alan, Kegg, Stephen, Waters, Laura, Orkin, Chole, Ustianowski, Andrew, Reeves, Iain, Leen, Clifford, Perry, Meghan, Portilla, Joaquin, Blanco, Jose Luis, Montejaro, Rocio, Domingo, Pere, Molina, Jean Michel, Katlama, Christine, Morlat, Philippe, Kenyon, Christopher, Puoti, Massimo, Rizzardini, Giuliano, Castagna, Antonella, Castelli, Francesco, Giacomelli, Andrea, Rockstroh, Jürgen, Esser, Stefan, Hoffmann, Christian, Mallon, Patrick · 2024 · The Lancet HIV

Abstract

Background The combination of dolutegravir plus rilpivirine has been studied in people with virologically suppressed HIV with no previous history of treatment failure or resistance. We investigated the potential to maintain viral suppression with dolutegravir plus rilpivirine in people with Lys103Asn mutations whose HIV was previously managed with other treatment regimens. Methods In this open-label pilot trial at 32 clinical sites in seven European countries, virologically suppressed, HBsAg-negative adults aged 18 years or older with HIV-1 and Lys103Asn mutations were randomly assigned (2:1) to switch to 50 mg dolutegravir plus 25 mg rilpivirine (given as a single tablet) once daily or to continue their current antiretroviral therapy regimen (control group). After 48 weeks, participants in the control group also switched to dolutegravir plus rilpivirine. Randomisation was stratified by country, and a computer-generated randomisation list with permuted blocks within strata was used to assign participants to treatment groups. The primary endpoints were virological failure (ie, two consecutive measurements of 50 copies or more of HIV RNA per mL at least 2 weeks apart) and virological suppression (the proportion of participants with fewer than 50 copies of HIV RNA per mL) at week 48 (week 96 data will be reported separately). Analyses were done in the modified intention-to-treat population, which included all participants who received at least one dose of the study medication. T…

Overview

Integrity signals

Registry

Crossref · 10.1016/s2352-3018(23)00292-8

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 22 references

Cited by

See all 6

Metadata

Authors
Moyle, G., Assoumou, L., de Castro, N., Post, F. A., Curran, A., Rusconi, S., De Wit, S., Stephan, C., Raffi, F., Johnson, M., Masia, M., Vera, J., Jones, B., Grove, R., Fletcher, C., Duffy, A., Morris, K., Pozniak, A., Moyle, G., de Castro, N., Post, F., Curran, A., Rusconi, S., De Wit, S., Stephan, C., Raffi, F., Johnson, M., Masia, M., Vera, J., Winston, A., Kegg, S., Waters, L., Orkin, C., Ustianowski, A., Reeves, I., Leen, C., Perry, M., Portilla, J., Blanco, J. L., Montejaro, R., Domingo, P., Molina, J. M., Katlama, C., Morlat, P., Kenyon, C., Puoti, M., Rizzardini, G., Castagna, A., Castelli, F., Giacomelli, A., Rockstroh, J., Esser, S., Hoffmann, C., & Mallon, P.
Affiliations
  • Inserm (FR)
  • ViiV Healthcare (United Kingdom) (GB)
  • GlaxoSmithKline (United Kingdom) (GB)
  • London School of Hygiene & Tropical Medicine (GB)
  • University of Milan (IT)
Venue
The Lancet HIV
Publisher
Elsevier BV
Published
2024-03
Volume
11
Issue
3
Pages
e156-e166
ISSN
2352-3018 (ISSN-L)
OpenAlex
W4392180047
Cited by
6
References
23
Citations by year
2026: 3 · 2025: 2 · 2024: 1
FWCI
2.08
Type
journal article
Language
en
Open access
Locations
  • The Lancet HIV (publishedVersion)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by)
  • Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
Funders
ViiV Healthcare UK
Topics
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
  • Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
Keywords
rilpivirine, HIV-1, K103N mutation, integrase inhibitor resistance, antiretroviral therapy switching, viral suppression, virological failure, integrase inhibitors, single-tablet regimen
MeSH terms
Rilpivirine, Dolutegravir, Adult, Heterocyclic Compounds, 3-Ring, HIV Seropositivity, Humans, Mutation, Oxazines, Pilot Projects, Piperazines, Pyridones, RNA, HIV-1, HIV Infections, Treatment Outcome, Anti-HIV Agents, Viral Load, Anti-Retroviral Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial. https://app.cochat.ai/papers/10.1016/s2352-3018(23)00292-8
The paper
Moyle, G., Assoumou, L., de Castro, N., Post, F. A., Curran, A., Rusconi, S., De Wit, S., Stephan, C., Raffi, F., Johnson, M., Masia, M., Vera, J., Jones, B., Grove, R., Fletcher, C., Duffy, A., Morris, K., Pozniak, A., Moyle, G., . . . Mallon, P. (2024). Switching to dolutegravir plus rilpivirine versus maintaining current antiretroviral therapy regimen in virologically suppressed people with HIV-1 and the Lys103Asn (K103N) mutation: 48-week results from a randomised, open-label pilot clinical trial. The Lancet HIV. https://doi.org/10.1016/s2352-3018(23)00292-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.